Breaking Research News from sources other than Breastcancer.org
Comments
-
You’re welcome Zarovka, thank you for your comments.
Heidihill, I like your comments too. On inflammation - why we need to fight it: from www.envita.com.
Envita is a very honest website. They go into detail on why we’re not getting the best treatments, including insurance companies, medicare, doctor education and more.
——————————————-
Chronic Inflammation
In Latin, the word "inflammation" means "I ignite, set alight" and like gasoline, that's exactly what it does to cancer. A microenvironment of chronic inflammation can increase the risk of cancer, bolster chemotherapy resistance and turn on oncogenes, genes that can turn cells into tumors.
Inflammation can become chronic if the cause of the inflammation persists or certain control mechanisms in charge of shutting down the process fail. When these inflammatory responses become chronic, cell mutation and proliferation can result, often creating an environment that is conducive to the development of cancer. The so-called "perfect storm" is an extreme challenge that cancer patients face.
-
Common drug may help battle aggressive breast cancer
Published Saturday 5 May 2018By Tim Newman
Fact checked by Jasmin Collier
Basal-like breast cancer affects women at a relatively young age and is challenging to treat. The discovery that a common drug for osteoporosis may halt its progress is welcome news.New research offers a potential avenue for the treatment of basal-like breast cancer.Basal-like breast cancer develops in younger women, and prognosis rates are the worst of any cancertype.Often caught at a late stage, the tumors are normally aggressive and spread quickly.Even when treatment is successful, basal-like breast cancer is more likely to recur and metastasize than other types.The reason why this type of cancer is so hard to treat is that the three major targets for therapy are not usually present. In these cases, it is referred to as triple-negative breast cancer.The vast majority of breast cancer drugs target estrogen receptors, progesterone receptors, or the hormone epidermal growth factor receptor 2. In about 10–20 percent of breast cancer cases, they are not present — but without them, most therapeutics have no teeth.New study-co author Prof. Chenfang Dong, from the Zhejiang University School of Medicine in Hangzhou, China, reiterates why research into this type of cancer is so pressing:"The highly aggressive nature and the absence of effective therapeutics for basal-like breast cancer make it a high priority to elucidate what determines its aggressiveness and identify potential therapeutic targets."Details of his latest study were published recently in the Journal of Experimental Medicine. -
I suspect that plenty of patients have been lowering dosages of prescribed medication for years (without telling their doctors). I know my mother did. She did not have cancer but she routinely chopped her various pills in half or quarters. Her doctors just didn’t seem to understand that it didn’t make sense to give a frail 93 year old the same amount as a young person weighing twice as much.
-
This isn't research per se but is something that should concern ALL of us, whether in the US or otherwise, since there may be a ripple effect in terms of support for research, etc.
-
Sara - I know that is true. Doesn't work with IV chemo unfortunately. However, we as always have the right to say no to treatment...
Will be trying to negotiate my Abraxane dose down a bit going forward.
Z
-
Thanks for posting "Breast Cancer Scrubbed from Government Website", Hopeful, wtf? That was over 5 months ago. Where's Joe Biden and the Moonshot?
-
Fifteen Things Physicians and Patients Should Question
https://www.aafp.org/dam/AAFP/documents/about_us/i... -
'World-first' call for exercise to be prescribed to all Australian cancer patients
-
Obamacare Premiums to Surge Next Year, Early Requests Show
https://www.bloomberg.com/news/articles/2018-05-07...
{disturbing}
-
Global Analysis of Advanced/Metastatic Breast Cancer: Decade Report (2005–2015)
TAKE-HOME MESSAGE
- Using results from four global qualitative and quantitative surveys of nearly 15,000 patients in 34 countries as well as a literature review, the authors provide an overview of metastatic breast cancer care gaps, resources, and support available for patients in different regions of the world. Modest outcome improvements have been reported over the last decade. However, patients still do not receive adequate information. Furthermore, quality of life may have declined over the past decade.
- A global effort of healthcare professionals, patients, families, and advocates is needed to improve patient outcomes and quality of life.
https://www.practiceupdate.com/c/67169/67/13/?elsc...
-
Time Trends of Overall Survival Among Metastatic Breast Cancer Patients in the Real-Life ESME Cohort
TAKE-HOME MESSAGE
- In this French, multicenter observational cohort of 15,085 patients with newly diagnosed metastatic breast cancer and full immunohistochemistry data, the authors evaluated the impact of year of diagnosis on overall survival. Of these patients, 9907 were HR+/HER2−, 2861 were HER2+, and 2317 were HR−/HER2−. The entire cohort had a median overall survival of 37.22 months. Year of diagnosis, age, subtype, disease-free interval, visceral metastases, and number of involved organs were independent predictors of overall survival. Year of diagnosis was a strong predictor of overall survival in HER2+ patients, but not in HR+/HER2− or HR−/HER2− patients.
- These data demonstrate improved overall survival in patients with HER2+ metastatic breast cancer, highlighting the need for new strategies for other subtypes.
- RESULTS: Median OS of the whole cohort was 37.22 months (95% confidence interval [CI], 36.3-38.04). Year of diagnosis was an independent predictor of OS (hazard ratio 0.98 [95% CI, 0.97-1.00], P = .01) together with age, subtype, disease-free interval, visceral metastases and number of organs involved. Median OS of HR+/HER2-, HER2+ and HR-/HER2- subcohorts was, respectively, 42.12 (95% CI, 40.90-43.10), 44.91 (95% CI, 42.51-47.90) and 14.52 (95% CI, 13.70-15.24) months. Year of diagnosis was a strong independent predictor of OS in HER2+ subcohort (hazard ratio 0.91 [95% CI, 0.88-0.94], P < .001), but not in HR+/HER2- nor HR-/HER2- subcohorts (hazard ratio 1.00 [95% CI, 0.98-1.01], P = .80 and 1.00 [95% CI, 0.97-1.02], P = .90, respectively).
-
Intrathecal Administration of Trastuzumab Is Feasible in Patients With HER2+ Breast Carcinomatous Meningitis
TAKE-HOME MESSAGE
- In this phase I dose-escalation study, 16 patients with leptomeningeal carcinomatosis from HER2+ breast cancer received intrathecal trastuzumab. No dose-limiting toxicity of trastuzumab was observed. Of these patients, 11 did not exhibit toxicities attributable to trastuzumab. Minor toxicities attributable to trastuzumab at 60-mg or higher dose levels included headache, nausea, vomiting, cervical pain, and peripheral neuropathy. Clinical responses were achieved in 3 patients, 7 had stable disease, and 4 had progressive disease.
- The recommended phase II weekly dose of intrathecal trastuzumab is 150 mg in patients with HER2+ breast cancer.
-
A Serum MicroRNA Signature Predicts Trastuzumab Benefit in HER2+ MBC
TAKE-HOME MESSAGE
- In this study, a miRNA microarray identified 13 miRNAs in the serum of patients with HER2+ metastatic breast cancer with a distinct response to trastuzumab treatment. Of these, four miRNAs (miR-940, miR-451a, miR-16-5p, and miR-17-3p) were used to create a signature predictive of survival using a LASSO model. These miRNAs are directly involved in regulating resistance to trastuzumab.
- This miRNA signature, which may predict trastuzumab benefit in patients with HER2+ metastatic breast cancer, warrants further validation in prospective clinical trials.
https://www.practiceupdate.com/c/67476/67/13/?elsc...
Abstract - Published: 24 April 2018:
https://www.nature.com/articles/s41467-018-03537-w
{This study was done in China. It's very new. Really interesting, IMO. Would be interested to hear if anyone's MO team has mentioned this in discussion. Thx.}
-
Lumpie - fascinating series of posts. Z
-
Hopeful8201: Thanks for posting about "Breast Cancer Info Scrubbed From Government Website." That is, indeed, disturbing.
-
Pressure to stay positive may be a negative for cancer patients
-
Exploring vitamin D metabolism and function in cancer
-
"The All of Us Research Program has a simple mission. We want to speed up health research breakthroughs. To do this, we're asking one million people to share health information. In the future, researchers can use this to conduct thousands of health studies."
https://www.joinallofus.org/en
-
I can't recall if we shared this before, but this would be a great tool for all surgeries! I wonder if any of our members have participated with a trial.
Light up malignant cells during surgery with infrared lighting.
-
The systemic response to surgery triggers the outgrowth of distant immune-controlled tumors in mouse models of dormancy. pub date: 2018 Apr 11
Abstract:
-
UTA researcher patents "roach motel" for cancer
-
Invasive cancers that are born to be bad show detectable differences from harmless tumors
-
ASCO: 2018 Treatment Algorithm for Metastatic HER2-Positive Breast Cancer
-
Hi Lumpie,
Thank you so much for all your work in posting these studies. I greatly appreciate it. How are you doing and feeling these days?
May you be well.
-
Hi couragement! I'm a little obsessive (but also a little random) with the research and reading... and how much I can do varies with my workload... but if I am finding interesting stuff, I figure I might as well share it!
I had an infusion yesterday. The last couple of times I have been so tired, i slept through 90% of it... which is not bad. Besides some fatigue and a few misc side effects, I am doing pretty well these days - thanks for asking. I have a scan coming up. Fingers crossed. Hope you are doing well. Thanks for reading. If you find any interesting articles, please share.
-
Israeli researchers say they have found a way to curb growth of cancer cells
-
Glyphosate shown to disrupt microbiome 'at safe levels', study claims
Study on rats said to show that the chemical, found in Monsanto's Roundup weedkiller, poses 'a significant public health concern'
https://www.theguardian.com/environment/2018/may/1...
{troubling}
-
Study Finds More Isn't Better for Widely Used Breast Cancer Drug
...women with a dangerous form of breast cancer have relied on Roche Holding AG's blockbuster drug Herceptin, taking the $76,700-a-year medicine for 12 months to fight off the disease. A new study finds that they may be able to cut their treatment in half.
https://www.bloomberg.com/news/articles/2018-05-16...
Same topic, NY Times:
https://mobile.nytimes.com/2018/05/16/health/breas...
-
This new beer is developed specifically for breast cancer patients
https://www.fastcompany.com/40572691/this-new-beer...
{Wonder if they'd wanna fund some meaningful research....?}
-
Categories
- All Categories
- 679 Advocacy and Fund-Raising
- 289 Advocacy
- 68 I've Donated to Breastcancer.org in honor of....
- Test
- 322 Walks, Runs and Fundraising Events for Breastcancer.org
- 5.6K Community Connections
- 282 Middle Age 40-60(ish) Years Old With Breast Cancer
- 53 Australians and New Zealanders Affected by Breast Cancer
- 208 Black Women or Men With Breast Cancer
- 684 Canadians Affected by Breast Cancer
- 1.5K Caring for Someone with Breast cancer
- 455 Caring for Someone with Stage IV or Mets
- 260 High Risk of Recurrence or Second Breast Cancer
- 22 International, Non-English Speakers With Breast Cancer
- 16 Latinas/Hispanics With Breast Cancer
- 189 LGBTQA+ With Breast Cancer
- 152 May Their Memory Live On
- 85 Member Matchup & Virtual Support Meetups
- 375 Members by Location
- 291 Older Than 60 Years Old With Breast Cancer
- 177 Singles With Breast Cancer
- 869 Young With Breast Cancer
- 50.4K Connecting With Others Who Have a Similar Diagnosis
- 204 Breast Cancer with Another Diagnosis or Comorbidity
- 4K DCIS (Ductal Carcinoma In Situ)
- 79 DCIS plus HER2-positive Microinvasion
- 529 Genetic Testing
- 2.2K HER2+ (Positive) Breast Cancer
- 1.5K IBC (Inflammatory Breast Cancer)
- 3.4K IDC (Invasive Ductal Carcinoma)
- 1.5K ILC (Invasive Lobular Carcinoma)
- 999 Just Diagnosed With a Recurrence or Metastasis
- 652 LCIS (Lobular Carcinoma In Situ)
- 193 Less Common Types of Breast Cancer
- 252 Male Breast Cancer
- 86 Mixed Type Breast Cancer
- 3.1K Not Diagnosed With a Recurrence or Metastases but Concerned
- 189 Palliative Therapy/Hospice Care
- 488 Second or Third Breast Cancer
- 1.2K Stage I Breast Cancer
- 313 Stage II Breast Cancer
- 3.8K Stage III Breast Cancer
- 2.5K Triple-Negative Breast Cancer
- 13.1K Day-to-Day Matters
- 132 All things COVID-19 or coronavirus
- 87 BCO Free-Cycle: Give or Trade Items Related to Breast Cancer
- 5.9K Clinical Trials, Research News, Podcasts, and Study Results
- 86 Coping with Holidays, Special Days and Anniversaries
- 828 Employment, Insurance, and Other Financial Issues
- 101 Family and Family Planning Matters
- Family Issues for Those Who Have Breast Cancer
- 26 Furry friends
- 1.8K Humor and Games
- 1.6K Mental Health: Because Cancer Doesn't Just Affect Your Breasts
- 706 Recipe Swap for Healthy Living
- 704 Recommend Your Resources
- 171 Sex & Relationship Matters
- 9 The Political Corner
- 874 Working on Your Fitness
- 4.5K Moving On & Finding Inspiration After Breast Cancer
- 394 Bonded by Breast Cancer
- 3.1K Life After Breast Cancer
- 806 Prayers and Spiritual Support
- 285 Who or What Inspires You?
- 28.7K Not Diagnosed But Concerned
- 1K Benign Breast Conditions
- 2.3K High Risk for Breast Cancer
- 18K Not Diagnosed But Worried
- 7.4K Waiting for Test Results
- 603 Site News and Announcements
- 560 Comments, Suggestions, Feature Requests
- 39 Mod Announcements, Breastcancer.org News, Blog Entries, Podcasts
- 4 Survey, Interview and Participant Requests: Need your Help!
- 61.9K Tests, Treatments & Side Effects
- 586 Alternative Medicine
- 255 Bone Health and Bone Loss
- 11.4K Breast Reconstruction
- 7.9K Chemotherapy - Before, During, and After
- 2.7K Complementary and Holistic Medicine and Treatment
- 775 Diagnosed and Waiting for Test Results
- 7.8K Hormonal Therapy - Before, During, and After
- 50 Immunotherapy - Before, During, and After
- 7.4K Just Diagnosed
- 1.4K Living Without Reconstruction After a Mastectomy
- 5.2K Lymphedema
- 3.6K Managing Side Effects of Breast Cancer and Its Treatment
- 591 Pain
- 3.9K Radiation Therapy - Before, During, and After
- 8.4K Surgery - Before, During, and After
- 109 Welcome to Breastcancer.org
- 98 Acknowledging and honoring our Community
- 11 Info & Resources for New Patients & Members From the Team